New inhaler shows promise for COPD patients
NCT ID NCT07252908
First seen Dec 08, 2025 · Last updated Jun 22, 2026 · Updated 23 times
Summary
This clinical trial tested a new inhaled powder called TQC3721 in 195 people with moderate to severe COPD. The study compared the drug to a placebo to see if it could improve lung function over four weeks. The goal was to find a safe and effective new treatment option for COPD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital Of ChengDu University
Chengdu, Sichuan, 610081, China
-
Chengdu Fifth People's Hospital
Chengdu, Sichuan, 610044, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
Guigang People's Hospital
Guigang, Guangxi, 537100, China
-
Heze Municipal Hospital
Heze, Shandong, 274000, China
-
Jiangmen Central Hospital
Jiangmen, Guangdong, 529000, China
-
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, 330006, China
-
Jiujiang First People's Hospital
Jiujiang, Jiangxi, 332000, China
-
Linfen People's Hospital
Linfen, Shanxi, 41000, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210000, China
-
Nuclear Industry 416 Hospital
Chengdou, Sichuan, 610051, China
-
Puyang Oilfield General Hospital
Puyang, Henan, 457001, China
-
Shanghai JiaoTong University of medicine Ruijin Hospital
Shanghai, Shanghai Municipality, 20025, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
Siping Central People's Hospital
Siping, Jilin, 136099, China
-
Suining Central Hospital
Suining, Sichuan, 629000, China
-
Taizhou central hospital (Taizhou university hospital）
Taizhou, Zhejiang, 31800, China
-
The 2th School of Medicine ,WMU/The 2th affiliated Hospital and Yuying Children's Hospital of WMU
Wenzhu, Zhejiang, 325027, China
-
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, 010000, China
-
The Fourth Central Hospital of Tianjin
Tianjin, Tianjin Municipality, 300140, China
-
The People's Hospital of Liuyang
Changsha, Hunan, 410000, China
-
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chognqing, 400010, China
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, 300052, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, Sichuan 610044, China
-
Xiangtan County People's Hospital
Xiangtan, Hunan, 411200, China
-
Yibin Second People's Hospital
Yibin, Sichuan, 644000, China
-
Yichang Central People's Hospital
Yichang, Hubei, 443003, China
-
Yixing People'S Hospital
Wuxi, Jiangsu, 214000, China
-
Zunyi Medical University Affiliated Hospital
Zunyi, Guizhou, 563000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQC3721 inhalation powder
What this could lead to
If successful, this could lead to a new inhaled treatment option for people with moderate to severe COPD, potentially improving lung function.
What could go wrong
This is an early Phase 2 trial with only 195 participants, so results may not apply to everyone. The drug may not show enough benefit or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.